Evaluation of Recombinant Growth Hormone Therapy to Prevent Muscle Atrophy in Patients With Anterior Cruciate Ligament Tears

Trial Profile

Evaluation of Recombinant Growth Hormone Therapy to Prevent Muscle Atrophy in Patients With Anterior Cruciate Ligament Tears

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Somatrogon (Primary)
  • Indications Knee injuries
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jan 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 27 Jan 2018 Planned primary completion date changed from 1 May 2018 to 1 Dec 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top